Drug guidance
High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
Condition
Endocrine and metabolic
1 April 2022
Published on 01 Apr 2022
Last Updated on 01 Apr 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing insulin glargine 300 units/ml on the Standard Drug List (SDL) for treating type 1 and 2 diabetes mellitus in view of unfavourable cost-effectiveness compared with insulin glargine 100 units/ml at the price proposed by the manufacturer, and low clinical need.
High-strength insulin glargine for treating diabetes mellitus PES (1 Apr 2022) [PDF, 126 KB]